197 related articles for article (PubMed ID: 26746655)
1. Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma.
Rausch S; Hennenlotter J; Scharpf M; Teepe K; Kühs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
J Cancer Res Clin Oncol; 2016 May; 142(5):937-47. PubMed ID: 26746655
[TBL] [Abstract][Full Text] [Related]
2. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.
Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311
[TBL] [Abstract][Full Text] [Related]
3. [Estimation of the diagnostic potential of APOD, PTOV1, and EPHA4 for prostatic neoplasms].
Allina DO; Andreeva YY; Zavalishina LE; Moskvina LV; Frank GA
Arkh Patol; 2016; 78(5):9-14. PubMed ID: 27804940
[TBL] [Abstract][Full Text] [Related]
4. Prostate tumor overexpressed 1 is a novel prognostic marker for hepatocellular carcinoma progression and overall patient survival.
Chen SP; Zhang LS; Fu BS; Zeng XC; Yi HM; Jiang N
Medicine (Baltimore); 2015 Jan; 94(4):e423. PubMed ID: 25634174
[TBL] [Abstract][Full Text] [Related]
5. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma.
Mai KT; Busca A; Belanger EC
Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746
[TBL] [Abstract][Full Text] [Related]
6. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
[TBL] [Abstract][Full Text] [Related]
7. Prostate Tumor Overexpressed 1 (PTOV1) Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Poor Survival Outcomes.
Yang Q; Lin H; Wu S; Lei F; Zhu X; Song L; Hong M; Guo L
PLoS One; 2015; 10(8):e0136448. PubMed ID: 26305455
[TBL] [Abstract][Full Text] [Related]
8. The role of prostate tumor overexpressed 1 in cancer progression.
Cánovas V; Lleonart M; Morote J; Paciucci R
Oncotarget; 2017 Feb; 8(7):12451-12471. PubMed ID: 28029646
[TBL] [Abstract][Full Text] [Related]
9. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract.
Ohtsuka Y; Kawakami S; Fujii Y; Koga F; Saito K; Ando N; Takizawa T; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1322-6. PubMed ID: 16686732
[TBL] [Abstract][Full Text] [Related]
10. T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival.
Yang M; Yu Q; Liu J; Fu W; Cao Y; Yu L; Shao S; Wang X; Niu H; Wang Y
J Surg Oncol; 2015 Sep; 112(4):430-5. PubMed ID: 26265374
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer.
Lei F; Zhang L; Li X; Lin X; Wu S; Li F; Liu J
BMC Cancer; 2014 Jun; 14():457. PubMed ID: 24947166
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study.
Florianova L; Xu B; Traboulsi S; Elmansi H; Tanguay S; Aprikian A; Kassouf W; Brimo F
World J Surg Oncol; 2015 Nov; 13():317. PubMed ID: 26577765
[TBL] [Abstract][Full Text] [Related]
13. Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.
Guo F; Feng L; Hu JL; Wang ML; Luo P; Zhong XM; Deng AM
Tumour Biol; 2015 Jan; 36(1):453-8. PubMed ID: 25270739
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.
Downes MR; Torlakovic EE; Aldaoud N; Zlotta AR; Evans AJ; van der Kwast TH
J Clin Pathol; 2013 Sep; 66(9):779-86. PubMed ID: 23775437
[TBL] [Abstract][Full Text] [Related]
15. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
16. Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival.
Jou YC; Tsai YS; Chen SY; Hsieh HY; Tsai HT; Tzai TS
Virchows Arch; 2016 Jun; 468(6):733-40. PubMed ID: 27003158
[TBL] [Abstract][Full Text] [Related]
17. Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract.
Scarpini S; Rouprêt M; Renard-Penna R; Camparo P; Cussenot O; Compérat E
Urol Oncol; 2012; 30(2):182-7. PubMed ID: 20189840
[TBL] [Abstract][Full Text] [Related]
18. Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression.
Alaña L; Sesé M; Cánovas V; Punyal Y; Fernández Y; Abasolo I; de Torres I; Ruiz C; Espinosa L; Bigas A; Y Cajal SR; Fernández PL; Serras F; Corominas M; Thomson TM; Paciucci R
Mol Cancer; 2014 Mar; 13():74. PubMed ID: 24684754
[TBL] [Abstract][Full Text] [Related]
19. Reduced 5-methylcytosine level as a potential progression predictor in patients with T1 or non-invasive urothelial carcinoma.
Chung CJ; Chang CH; Chuu CP; Yang CR; Chang YH; Huang CP; Chen WC; Chung MC; Chang H
Int J Mol Sci; 2014 Dec; 16(1):677-90. PubMed ID: 25561224
[TBL] [Abstract][Full Text] [Related]
20. PTOV1 is overexpressed in human high-grade malignant tumors.
Fernández S; Mosquera JL; Alaña L; Sanchez-Pla A; Morote J; Ramón Y Cajal S; Reventós J; de Torres I; Paciucci R
Virchows Arch; 2011 Mar; 458(3):323-30. PubMed ID: 21181414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
